Lenalidomide-Induced Second Cancer Risk Limited to Multiple Myeloma

(MedPage Today) -- Lenalidomide (Revlimid)-induced second primary malignancies appear to be limited to patients with multiple myeloma, according to a systematic review and meta-analysis.
While there was no significant increase in the risk of second...